ImmunityBio
IBRX
IBRX
149 hedge funds and large institutions have $200M invested in ImmunityBio in 2022 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 20 closing their positions.
Holders
149
Holders Change
+8
Holders Change %
+5.67%
% of All Funds
2.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
29
Increased
44
Reduced
39
Closed
20
Calls
$2.39M
Puts
$4.31M
Net Calls
-$1.92M
Net Calls Change
+$2.51M
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$6.02M |
| 2 |
2
State Street
Boston,
Massachusetts
|
$37.9M |
| 3 |
OIM
3
Oracle Investment Management
Greenwich,
Connecticut
|
$2.24M |
| 4 |
4
Millennium Management
New York
|
$3.42M |
| 5 |
5
Citadel Advisors
Miami,
Florida
|
$1.91M |
Top Sellers
| 1 |
1
Renaissance Technologies
New York
|
$0 |
| 2 |
2
Citigroup
New York
|
$523K |
| 3 |
3
D.E. Shaw & Co
New York
|
$534K |
| 4 |
4
BlackRock
New York
|
$28.7M |
| 5 |
5
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
$4.29M |
